My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Prophase Labs (PRPH)
NASDAQ:PRPH
PRPH nasdaq
United States
Prophase Labs

Prophase Labs Stock Analysis & Ratings

Prophase Labs Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Prophase Labs stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

PRPH

PRPH Stock Stats

Previous Close$6.58
Open$6.65
Bid0 x 0
Ask0 x 0
Today’s Range$6.42 - $7
52-Week Range$4.41 - $16.04
Volume156.77K
Average Volume74.58K
Market Cap$102.69M
Beta-0.14
P/E Ratio-17.8
EPS-0.37
Earnings DateMar 29, 2022
Ex-Dividend DateMay 24, 2021

Company Description

Prophase Labs

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. Its products include TK supplement. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Doylestown, PA.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Ted Karkus
Employees
95
ISIN
US74345W1080
Address
711 Stewart Avenue, Garden City, NY, 11530, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

PRPH FAQ

What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $4.41 and its highest was $16.04 in the past 12 months.
    What is Prophase Labs’s market cap?
    Prophase Labs’s market cap is $102.69M.
      What is Prophase Labs’s price target?
      Currently, no data Available
      What do analysts say about Prophase Labs?
      Prophase Labs’s analyst rating consensus is a ‘Hold. This is based on the ratings of 1 Wall Streets Analysts.
        When is Prophase Labs’s upcoming earnings report date?
        Prophase Labs’s upcoming earnings report date is Mar 29, 2022 which is in 115 days.
          How were Prophase Labs’s earnings last quarter?
          Prophase Labs released its earnings results on Nov 12, 2021. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.085 by -$0.175.
            Is Prophase Labs overvalued?
            According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
              Does Prophase Labs pay dividends?
              Prophase Labs pays a Notavailable dividend of $0.3 which represents an annual dividend yield of 4.56%. Prophase Labs’s last Notavailable dividend payment was on Jun 03, 2021. Prophase Labs’s upcoming ex-dividend date is May 24, 2021
                What is Prophase Labs’s EPS estimate?
                Prophase Labs’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Prophase Labs have?
                Prophase Labs has 15,510,000 shares outstanding.
                  What happened to Prophase Labs’s price movement after its last earnings report?
                  Prophase Labs reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.085. Following the earnings report the stock price went up 3.627%.
                    Which hedge fund is a major shareholder of Prophase Labs?
                    Currently, no hedge funds are holding shares in PRPH

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis